Phase I/II Open Label Non-randomised Safety and Efficacy Study of the Viral Vectored ChAd-MVA 5T4 Vaccine in Combination With PD-1 Checkpoint Blockade in Low- or Intermediate-risk Localized or Locally Advanced Prostate Cancer and Advanced Metastatic Prostate Cancer
Latest Information Update: 01 Jul 2025
At a glance
- Drugs ChAdOx1-MVA 5T4 vaccine (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADVANCE
Most Recent Events
- 25 Jun 2025 Status changed from active, no longer recruiting to discontinued because the trial could not restart again after the COVID pandemic.
- 27 Nov 2020 Planned End Date changed from 10 May 2021 to 10 Jul 2021.
- 27 Nov 2020 Planned primary completion date changed from 10 Dec 2020 to 10 Mar 2021.